The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Aventis Pharma competitive analysis

Loading summary...

Latest patents of Aventis Pharma opposed by its competitors

Explore Aventis Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2493466
Mar 10, 2021Novel Antitumoral Use Of Cabazitaxel13
EP3294285
Dec 18, 2019Cabazitaxel And Its Use For Treating Cancer10
EP2678011
Jun 26, 2019Antitumoral Combination Comprising Cabazitaxel And Cisplatin1

Latest PTAB cases involving Aventis Pharma

Discover the latest PTAB cases involving Aventis Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 13, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Aventis Pharma

IPR2019-00136Oct 31, 2018NEPTUNE GENERICSAVENTIS PHARMAInstitution Denied
IPR2016-00712Mar 15, 2016MYLAN LABORATORIESAVENTIS PHARMAFinal Written Decision
IPR2016-00627Feb 17, 2016MYLAN LABORATORIESAVENTIS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Aventis Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AVENTIS PHARMA - 24 - 3
ACCORD HEALTHCARE39 - 4 -
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTEL6 - - -
GENERICS UK214 - - -